Literature DB >> 31662494

Motor speech patterns in Huntington disease.

Sarah K Diehl1, Antje S Mefferd1, Ya-Chen Lin1, Jessie Sellers1, Katherine E McDonell1, Michael de Riesthal1, Daniel O Claassen2.   

Abstract

OBJECTIVE: Dysarthric speech of persons with Huntington disease (HD) is typically described as hyperkinetic; however, studies suggest that dysarthria can vary and resemble patterns in other neurologic conditions. To test the hypothesis that distinct motor speech subgroups can be identified within a larger cohort of patients with HD, we performed a cluster analysis on speech perceptual characteristics of patient audio recordings.
METHODS: Audio recordings of 48 patients with mild to moderate dysarthria due to HD were presented to 6 trained raters. Raters provided scores for various speech features (e.g., voice, articulation, prosody) of audio recordings using the classic Mayo Clinic dysarthria rating scale. Scores were submitted to an unsupervised k-means cluster analysis to determine the most salient speech features of subgroups based on motor speech patterns.
RESULTS: Four unique subgroups emerged from the cohort of patients with HD. Subgroup 1 was characterized by an abnormally fast speaking rate among other unique speech features, whereas subgroups 2 and 3 were defined by an abnormally slow speaking rate. Salient speech features for subgroup 2 overlapped with subgroup 3; however, the severity of dysarthria differed. Subgroup 4 was characterized by mild deviations of speech features with typical speech rate. Length of CAG repeats, Unified Huntington's Disease Rating Scale total motor score, and percent intelligibility were significantly different for pairwise comparisons of subgroups.
CONCLUSION: This study supports the existence of distinct presentations of dysarthria in patients with HD, which may be due to divergent pathologic processes. The findings are discussed in relation to previous literature and clinical implications.
© 2019 American Academy of Neurology.

Entities:  

Mesh:

Year:  2019        PMID: 31662494      PMCID: PMC6913327          DOI: 10.1212/WNL.0000000000008541

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  25 in total

1.  Impaired motor speech performance in Huntington's disease.

Authors:  Sabine Skodda; Uwe Schlegel; Rainer Hoffmann; Carsten Saft
Journal:  J Neural Transm (Vienna)       Date:  2013-11-13       Impact factor: 3.575

2.  Handwriting movement kinematics for quantifying extrapyramidal side effects in patients treated with atypical antipsychotics.

Authors:  Michael P Caligiuri; Hans-Leo Teulings; Charles E Dean; Alexander B Niculescu; James B Lohr
Journal:  Psychiatry Res       Date:  2010-04-09       Impact factor: 3.222

3.  Influence of cognitive function on speech and articulation rate in multiple sclerosis.

Authors:  Jonathan D Rodgers; Kris Tjaden; Lynda Feenaughty; Bianca Weinstock-Guttman; Ralph H B Benedict
Journal:  J Int Neuropsychol Soc       Date:  2012-10-12       Impact factor: 2.892

4.  The effect of rate control on the intelligibility and naturalness of dysarthric speech.

Authors:  K M Yorkston; V L Hammen; D R Beukelman; C D Traynor
Journal:  J Speech Hear Disord       Date:  1990-08

Review 5.  The incidence and prevalence of Huntington's disease: a systematic review and meta-analysis.

Authors:  Tamara Pringsheim; Katie Wiltshire; Lundy Day; Jonathan Dykeman; Thomas Steeves; Nathalie Jette
Journal:  Mov Disord       Date:  2012-06-12       Impact factor: 10.338

6.  Acoustic analysis of voice in Huntington's disease patients.

Authors:  María Jesús Velasco García; Ignacio Cobeta; Gonzalo Martín; Hortensia Alonso-Navarro; Félix Javier Jimenez-Jimenez
Journal:  J Voice       Date:  2010-02-04       Impact factor: 2.009

7.  Evidence for more widespread cerebral pathology in early HD: an MRI-based morphometric analysis.

Authors:  H D Rosas; W J Koroshetz; Y I Chen; C Skeuse; M Vangel; M E Cudkowicz; K Caplan; K Marek; L J Seidman; N Makris; B G Jenkins; J M Goldstein
Journal:  Neurology       Date:  2003-05-27       Impact factor: 9.910

8.  In vivo evidence of cerebellar atrophy and cerebral white matter loss in Huntington disease.

Authors:  C Fennema-Notestine; S L Archibald; M W Jacobson; J Corey-Bloom; J S Paulsen; G M Peavy; A C Gamst; J M Hamilton; D P Salmon; T L Jernigan
Journal:  Neurology       Date:  2004-09-28       Impact factor: 9.910

Review 9.  Huntington disease: clinical, genetic, and social aspects.

Authors:  M A Nance
Journal:  J Geriatr Psychiatry Neurol       Date:  1998       Impact factor: 2.680

10.  Unified Huntington's Disease Rating Scale: reliability and consistency. Huntington Study Group.

Authors: 
Journal:  Mov Disord       Date:  1996-03       Impact factor: 10.338

View more
  2 in total

1.  State-of-the-art pharmacological approaches to reduce chorea in Huntington's disease.

Authors:  Jessie S Gibson; Daniel O Claassen
Journal:  Expert Opin Pharmacother       Date:  2021-02-08       Impact factor: 4.103

2.  Dysarthria Subgroups in Talkers with Huntington's Disease: Comparison of Two Data-Driven Classification Approaches.

Authors:  Daniel Kim; Sarah Diehl; Michael de Riesthal; Kris Tjaden; Stephen M Wilson; Daniel O Claassen; Antje S Mefferd
Journal:  Brain Sci       Date:  2022-04-13
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.